Furthermore, after Samadder et al. reported increased heritable variants in solid cancers by multigene vs. targeted testing [118] and Uson et al. reported that universal multigene panel testing increased the detection of the heritable germline mutations associated with CRC (15.5% harbored 62 pathogenic variants with MSH2 among the most common genes) [119], the National Comprehensive Cancer Network recommended germline multigene panel testing for all individuals younger than 50 years with CRC. The gene discussed is MSH2; the disease is colorectal carcinoma.